Key facts
- Notable investors include Zijin Hi-Tech Venture Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Nanjing Anyang Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Nanjing Anyang Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nanjing Anyang Biotechnology
Developer of in vitro diagnostic raw materials designed to advance the accuracy and reliability of medical testing. The company's product offers proprietary antigen and antibody technologies, multiple detection platform compatibility, and scalable manufacturing capabilities, enabling diagnostic manufacturers and healthcare providers to deliver precise test results and support improved disease detection and management.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2021
- Website
- anyonbio.com/
- Ownership
- Privately Held (backing)
Nanjing Anyang Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nanjing Anyang Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nanjing Anyang Biotechnology in its N-PORT filings yet. We sweep new filings monthly.